Figure 2.

Survival impact of E-cadherin expression and sequence analysis of CDH1 exon 9 missense mutations. (a) Overall survival in metastatic gastric or OGJ cancer patients treated with cetuximab plus FUFOX was analysed by the Kaplan-Meier method after stratification of patients according to their E-cadherin expression level (score 0, 1+, 2+ versus 3+). The log-rank test statistical analysis indicates a trend between high E-cadherin expression levels and increased OS (P = 0.124). (b) In the tumours of two patients, CDH1 exon 9 missense mutations were detectable and caused amino acid changes D402H or A408V.